From the Journals

Cisplatin-Free Toripalimab Tested for Head and Neck Cancer

Researchers note reduced rates of vomiting, fatigue, anemia, and leukopenia compared with standard therapy.

Share

A phase 3 trial examining toripalimab, combined with chemotherapy and radiotherapy without concurrent cisplatin, showed comparable efficacy and reduced toxicity in locoregionally advanced nasopharyngeal carcinoma patients. With a median follow-up of 37 months, the 3-year failure-free survival was 88.3% in the cisplatin-sparing group versus 87.6% in the standard group. Adverse events such as vomiting and anemia were less frequent without cisplatin. The study involved 532 patients from 13 hospitals in China and highlighted optimism for future research with ongoing trials on PD-1 blockade regimens.

Original Source(s)

Cisplatin-Free Toripalimab Tested for Head and Neck Cancer

Researchers note reduced rates of vomiting, fatigue, anemia, and leukopenia compared with standard therapy.

  • by Stanley Gajete

  • September 4, 2025

  • 3 min

Related Content

Tracking Opioid Refills After Surgery

Researchers evaluated perioperative and postdischarge factors associated with opioid refill prescriptions during the first 90 days after inpatient otolaryngology–head and neck surgery.

Neck Swelling, Dysphagia, and Jaw Pain: What’s Your Diagnosis?

A rare carotid artery pseudoaneurysm complicated by MRSA infection, septic arthritis, and an incidental thigh tumor challenged clinicians but was successfully treated with surgery and targeted antibiotics.

Chronic Cough Linked to GLP-1 Agonists 

New research suggests popular diabetes and weight-loss drugs may trigger persistent respiratory symptoms beyond their known gastrointestinal effects.